# Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease

> **NCT03352557** · PHASE2 · TERMINATED · sponsor: **Biogen** · enrollment: 654 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** BIIB092
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03352557
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-05-03
- **Primary completion:** 2021-08-30
- **Final completion:** 2021-08-30
- **Target enrollment:** 654 (ACTUAL)
- **Why stopped:** The study (NCT03352557) was terminated based on lack of efficacy following the placebo-controlled period readout.
- **Last updated:** 2022-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03352557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03352557, "Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT03352557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*